Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Genomics England

- PMLiVE

Axovant licenses another gene therapy as new strategy beds in

Group pursues gene therapy strategy

- PMLiVE

Vertex calls NHS England ‘outrageous’ as Orkambi talks stall again

Public row about confidential pricing talks drags on

SWITCHED ONcology

We bring together the experts. The patients. The scientists. The technologists. The creatives. We unite powerful insights to make science mean something real. We are stronger together. We are Switched...

Havas Lynx

18 SWITCHED ONcology: The Big Communication

Matching unprecedented clinical advances in immuno-oncology with transformative communication

Havas Lynx

Medical information in precision medicine

Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine.

Blue Latitude Health

- PMLiVE

May earmarks £20bn for the NHS – but experts say it’s not enough

But claims of a “Brexit dividend” are rubbished

- PMLiVE

ACT immunotherapy cures terminal breast cancer patient

The new approach focuses on mutations rather than cancer type

Combination therapies in oncology: The benefits of integrated insights

14 June 2018 11am EDT | 8am PDT | 4pm BST | 5pm CE

Research Partnership

Bayer symbol

Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

Bayer and Loxo hopeful about novel biomarker-led cancer treatment

- PMLiVE

Daily Brief: GDPR and NHS Opt Out Day, BioMarin’s new rare disease approval and more

It's not just the GDPR's big day, plus news from Medigene and Pfizer

Eli Lilly HQ

Lilly adds AurKa Pharma to oncology buying spree

Lilly is buying back its former drug after just two years

Eli Lilly HQ

Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline

Armo is developing IL-10 drugs for potential combination with established immunotherapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links